<DOC>
	<DOCNO>NCT02023697</DOCNO>
	<brief_summary>This study assess different dos regimens radium-223 dichloride incidence symptomatic skeletal event . Eligible subject must castration resistant prostate cancer 2 skeletal metastasis document within 8 week randomization . Subjects randomize one 3 treatment arm 1:1:1 fashion : standard regimen radium-223 dichloride 50 kBq/kg ( 55 kBq/kg implementation NIST update ) injection every month 6 month , high dose regimen 80 kBq/kg ( 88 kBq/kg implementation NIST update ) injection every month 6 month extend duration regimen 50 kBq/kg ( 55 kBq/kg implementation NIST update ) injection every month 12 month . Following treatment phase , subject follow every 12 week minimum 2 year , point enter long term follow-up period see every 6 month 7 year last dose radium dichloride . Symptomatic skeletal event safety endpoint assess clinic visit . Pain analgesic use data collect every 4 week Week 48 . Additionally , radiological assessment include MRI/CT abdomen pelvis chest CT , well technetium-99 bone scan perform Weeks 8 , 16 , 24 continue every 12 week thereafter disease progression document either bone soft tissue . Radiological imaging evaluate blinded central review .</brief_summary>
	<brief_title>Standard Dose Versus High Dose Versus Extended Standard Dose Radium-223 Dichloride Castration-resistant Prostate Cancer Metastatic Bone</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate Castrationresistant disease define : Serum testosterone level : ≤ 50 ng/dL ( 1.7 nmol/L ) Bilateral orchiectomy maintenance androgen ablation therapy luteinizinghormonereleasing hormone ( LHRH ) agonist antagonist , polyestradiol phosphate Serum PSA ( Prostate specific antigen ) progression define 2 subsequent increase PSA previous reference value ( minimum 2 ng/mL [ μg/L ] ) OR Radiographic evidence disease progression bone ( accord Prostate Cancer Clinical Trials Working Group 2 [ PCWG2 ] criterion ) without PSA progression Eastern Cooperative Oncology Group performance status ( ECOG PS ) 0 2 . In case ECOG PS 2 , PS due metastatic prostate cancer bone . Two skeletal metastasis ( ≥ 2 hot spot ) bone scintigraphy within 8 week randomization History visceral metastasis , visceral metastasis Lymphadenopathy lymph node exceed 3 cm short axis diameter Central nervous system ( CNS ) metastases Treatment cytotoxic chemotherapy prostate cancer within previous 4 week prior randomization , plan treatment cytotoxic chemotherapy agent prostate cancer treatment period followup Chronic condition associate nonmalignant abnormal bone growth ( e.g . confirm Paget 's disease bone ) Prior treatment radium223 dichloride Prior systemic radiotherapy hemibody external radiotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>